Generics - Pharmaceutical, Antibiotics and Infectious diseases, Mylan Laboratories

High incidence and inadequate treatments boost prospects of HIV, Chagas, Dengue and influenza H1N1 drugs in Latin America

High incidence and inadequate treatments boost prospects of HIV, Chagas, Dengue and influenza H1N1 drugs in Latin America

17-03-2014

The high incidence of human immunodeficiency virus (HIV), Chagas, dengue and influenza H1N1, as well…

Anti-viralsAntibiotics and Infectious diseasesGenericsMarkets & MarketingPharmaceuticalSouth America

Bayer in settlement over Cipro pricing

04-09-2013

A partial settlement has been reached in a US class action law suit involving the prescription antibiotic…

Antibiotics and Infectious diseasesBayerCiproGenericsLegalNorth AmericaPharmaceuticalPricing

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds

20-06-2013

Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products

30-05-2013

UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

Novo A/S acquires Norway's Xellia Pharmaceuticals in $700 million deal

21-05-2013

Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in Novo Nordisk…

Antibiotics and Infectious diseasesGenericsMergers & AcquisitionsNovo A/SNovo NordiskPharmaceuticalXellia Pharmaceuticals

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone

02-05-2013

US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

Anti-infective market in sub-Saharan Africa set to reach $377 million in 2018

05-03-2013

The high incidence of infectious diseases in sub-Saharan Africa is expected to sustain the demand for…

Antibiotics and Infectious diseasesGenericsMarkets & MarketingPharmaceuticalRest of the World

India's Macleods Pharma to invest $25 million in production in Russia; Ferring to start manufacturing

14-12-2012

Indian drugmaker Macleods plans to invest up to 700 million roubles (around $25 million) in the construction…

Antibiotics and Infectious diseasesEuropeFerring PharmaceuticalsGenericsIzvarino PharmaMacleods PharmaceuticalsOncologyPharmaceuticalProduction

Major constraints in the hospital-treated infections drug market include generic erosion

06-12-2012

The hospital-treated infections (HTI) drug market, the loss of patent protection for key branded products…

Antibiotics and Infectious diseasesGenericsGlobalMarkets & MarketingPharmaceuticalResearch

UK's NICE launches new medicines advisory service

15-07-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) last Friday launched…

Antibiotics and Infectious diseasesAstellas PharmaBiotechnologyDificlirEuropeGenericsPharmaceuticalRegulation

Teva settles Nuvigil patent litigation with Mylan, which debuts generic Doryx

01-05-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world's largest generics companies, said…

Antibiotics and Infectious diseasesDoryxGenericsLegalMergers & AcquisitionsMylan LaboratoriesNeurologicalNorth AmericaNuvigilPatentsPharmaceuticalTeva Pharmaceutical IndustriesWarner Chilcott

ViroPharma stock plunges on bad news for Vancocin; Sanofi patents invalidated

11-04-2012

ViroPharma I (Nasdaq: VPHM) saw its shares plunge 19% to $23.25 yesterday after it announced that the…

Antibiotics and Infectious diseasesApotexGenericsHospiraLegalNorth AmericaOncologyPatentsPharmaceuticalRegulationSanofiTaxotereVancocinViroPharmaWatson Pharmaceuticals

Hospira challenges Cubist patents on Cubicin

10-02-2012

US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) says that it has received a Paragraph IV Notice Letter…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsGenericsHospiraNorth AmericaPatentsPharmaceuticalResearch

Back to top